SecBot SecBot
8-K ·Filed Sep 15, 2026

GTBP

GT Biopharma, Inc.
BEARISH
Impact 7/10
Horizonimmediate Processed2mo ago SEC0001493152-26-042672
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ▼ Bearish

This is a highly dilutive PIPE financing by a micro-cap biotech with a $21M market cap. The 10% OID, full-ratchet anti-dilution, and greenshoe option signal desperate capital raising. Common stock will face massive overhang. Monitor for shareholder vote on the 19.99% issuance cap and any subsequent Greenshoe exercises, which would further reset the conversion price lower. The stock is likely to trade down significantly as the market prices in the dilution.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$9.00
T+0 close · Sep 15, 2026 · via day close
Latest settled
−27.78%
T+20 · $6.50 · next T+60 in 22d
Vs SPY
−30.76%
α at T+20
Latest observation
−53.54%
T+43 · FF3 residual α
  1. T+0 · Sep 15 $9.00entry
  2. T+1 · 2mo ago −13.11%α −13.44% · $7.82
  3. T+5 · 8w ago −20.44%α −21.26% · $7.16
  4. T+20 · 5w ago −27.78%α −30.76% · $6.50
  5. T+44 · todayOpen
  6. T+60 · in 22d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GT Biopharma entered into a securities purchase agreement to sell up to 41,778 shares of Series M 10% Convertible Preferred Stock and warrants for gross proceeds of up to $8,277,778 ($7,450,000 net after a 10% original issue discount). The offering includes a $30M greenshoe option and is highly dilutive, with a conversion/exercise price of $6.10 per share, subject to further price resets. The company also filed a Certificate of Designation for the preferred stock and a Registration Rights Agreement. This is a distressed financing by a micro-cap biotech with a $21M market cap, signaling acute capital needs and severe dilution risk for common shareholders.

Key Financial Metrics

Deal Value
$8.3M
Offering Size
$8.3M

Key Facts

  • Company sold up to 41,778 shares of Series M 10% Convertible Preferred Stock for aggregate gross proceeds of up to $8,277,778 (net $7,450,000 after 10% OID).
  • Investors receive common stock warrants for 100% of conversion shares, exercisable at $6.10 for 5 years.
  • Greenshoe option allows investors to purchase up to an additional $33.3M stated value of preferred stock ($30M purchase price).
  • Conversion price of $6.10 is subject to further downward adjustment via a price reset mechanism tied to Greenshoe exercises, with a floor of $1.282.
  • Company must seek shareholder approval to issue shares exceeding 19.99% of outstanding common stock (Issuable Maximum of 360,695 shares).
  • Lock-up agreements from directors, officers, and 10%+ stockholders are part of the transaction.
  • Registration rights granted for resale of underlying shares; failure to register triggers 1.5% monthly liquidated damages.

Financial Impact

Up to $8.28M gross proceeds ($7.45M net) from the initial closing, with potential for up to $30M additional from greenshoe. Dilution is severe: at $6.10 conversion price, full conversion of initial preferred stock alone would add ~1.36M shares (assuming no floor), dwarfing the current ~3.4M share count implied by a $21M market cap at ~$6.17/share.

dilutionshare countcash balance

Risk Factors

  • Extreme dilution to common shareholders from conversion of preferred stock and exercise of warrants.
  • Conversion price reset mechanism (Greenshoe) could drive conversion price well below $6.10, increasing dilution.
  • Company may fail to obtain shareholder approval for issuance above 19.99%, creating legal and operational risk.
  • Micro-cap biotech with no disclosed revenue or pipeline progress; financing suggests cash burn is high and capital markets access is limited.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-042672
Exhibit: ex10-2.htm0001493152-26-042672
Exhibit: ex3-1.htm0001493152-26-042672

Track record

12 reports on GTBP

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +41.62% at T+60 after the Aug 14, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 3/10 Entry $3.72 Now $3.54 −4.97% settles Feb 12
  2. Oct 21, 202627d ago EFFECT Bearish 6/10 Entry $5.41 Now $3.54 +34.66% settles Jan 19
  3. Oct 13, 20264w ago DEF 14A Bearish 7/10 Entry $6.21 Now $3.54 +43.08% settles Jan 11
  4. Oct 9, 20265w ago S-1 Bearish 7/10 Entry $6.80 Now $3.54 +48.01% settles Jan 7
  5. Sep 25, 20267w ago 8-K Neutral 3/10 Entry $6.80 Now $3.54 −48.01% settles Dec 22
  6. Sep 15, 20268w ago 8-K Bearish 7/10 Viewing Entry $9.00 Now $3.54 +60.72% settles Dec 9
  7. Sep 3, 202610w ago 8-K Neutral 4/10 Entry $0.2524 Now $3.54 +1300.55% settles Nov 30
  8. Aug 14, 202613w ago Press Release Bearish 5/10 Entry $0.2960 to $0.1728 Now $3.54 −1094.26% ▲ +41.62% +38.58% vs SPY
  9. May 22, 202625w ago 8-K Bearish 7/10 Entry $0.4400 to $0.2754 Now $3.54 −703.41% ▲ +37.41% +40.60% vs SPY
  10. Apr 30, 202628w ago S-1 Bearish 7/10 Entry $0.3430 to $0.3167 Now $3.54 −930.61% ▲ +7.67% +10.74% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 15, 2026